{"id":"fimasartan","rwe":[{"pmid":"40947318","year":"2025","title":"Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.","finding":"","journal":"Clinical therapeutics","studyType":"Clinical Study"},{"pmid":"40923512","year":"2025","title":"Letter to the Editor: Fimasartan-Induced Liver Injury and Update on Hepatotoxicity Risks.","finding":"","journal":"Journal of Korean medical science","studyType":"Clinical Study"},{"pmid":"40818015","year":"2025","title":"Eco-friendly Nano-scale Bio-analytical Insights for Spectrofluorimetric Estimation of Fimasartan Using Integrated Approach of Enhanced Microwave-assisted Hantzsch Reaction and Multicolored Analytical Chemistry.","finding":"","journal":"Journal of fluorescence","studyType":"Clinical Study"},{"pmid":"39771560","year":"2024","title":"Heterotropic Activation of Cytochrome P450 3A4 by Perillyl Alcohol.","finding":"","journal":"Pharmaceutics","studyType":"Clinical Study"},{"pmid":"39405004","year":"2024","title":"Novel Fimasartan Fluidized Solid Dispersion and Its Tablet: Preparation, Crystallinity, Solubility, Dissolution, and Pharmacokinetics in Beagle Dogs.","finding":"","journal":"European journal of drug metabolism and pharmacokinetics","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Type-1 angiotensin II receptor","category":"target"},{"label":"AGTR1","category":"gene"},{"label":"C09CA10","category":"atc"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"kanarb","offLabel":[],"synonyms":["fimasartan","kanarb","fimasartan potassium","fimasartan potassium hydrate","fimasartan potassium trihydrate","BR-A-657"],"timeline":[{"date":"2010-09-01","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval"}],"approvals":[{"date":"2010-09-01","orphan":false,"company":"","regulator":"Korean Food and Drug Administration (KFDA)"}],"brandName":"Kanarb","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Type-1 angiotensin II receptor","targets":[{"gene":"AGTR1","source":"DrugCentral","target":"Type-1 angiotensin II receptor","protein":"Type-1 angiotensin II receptor"}],"modality":"Small Molecule","explanation":"Think of it like a traffic jam: angiotensin II is like a traffic cop that tells blood vessels to narrow and slow down. Kanarb is like a traffic cop that tells the traffic cop to stand down, allowing blood vessels to relax and blood to flow more easily. This helps lower blood pressure and reduce the risk of heart disease.","oneSentence":"Kanarb works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.","technicalDetail":"Kanarb is a selective antagonist of the angiotensin II type 1 receptor (AT1R), which is a key component of the renin-angiotensin-aldosterone system (RAAS). By blocking the action of angiotensin II on AT1R, Kanarb reduces vasoconstriction, decreases blood pressure, and has a protective effect on the kidneys."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4906","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FIMASARTAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FIMASARTAN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:28:04.853677","biosimilars":[],"competitors":[{"drugName":"losartan","drugSlug":"losartan","fdaApproval":"1995-04-14","patentExpiry":"Oct 7, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eprosartan","drugSlug":"eprosartan","fdaApproval":"1997-12-22","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valsartan","drugSlug":"valsartan","fdaApproval":"1996-12-23","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"irbesartan","drugSlug":"irbesartan","fdaApproval":"1997-09-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"candesartan cilexetil","drugSlug":"candesartan-cilexetil","fdaApproval":"1998-06-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telmisartan","drugSlug":"telmisartan","fdaApproval":"1998-11-10","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"olmesartan medoxomil","drugSlug":"olmesartan-medoxomil","fdaApproval":"2002-04-25","genericCount":25,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azilsartan medoxomil","drugSlug":"azilsartan-medoxomil","fdaApproval":"2011-02-25","relationship":"same-class"}],"genericName":"fimasartan","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"losartan","brandName":"losartan","genericName":"losartan","approvalYear":"1995","relationship":"same-class"},{"drugId":"eprosartan","brandName":"eprosartan","genericName":"eprosartan","approvalYear":"1997","relationship":"same-class"},{"drugId":"valsartan","brandName":"valsartan","genericName":"valsartan","approvalYear":"1996","relationship":"same-class"},{"drugId":"irbesartan","brandName":"irbesartan","genericName":"irbesartan","approvalYear":"1997","relationship":"same-class"},{"drugId":"candesartan-cilexetil","brandName":"candesartan cilexetil","genericName":"candesartan cilexetil","approvalYear":"1998","relationship":"same-class"},{"drugId":"telmisartan","brandName":"telmisartan","genericName":"telmisartan","approvalYear":"1998","relationship":"same-class"},{"drugId":"olmesartan-medoxomil","brandName":"olmesartan medoxomil","genericName":"olmesartan medoxomil","approvalYear":"2002","relationship":"same-class"},{"drugId":"azilsartan-medoxomil","brandName":"azilsartan medoxomil","genericName":"azilsartan medoxomil","approvalYear":"2011","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07421414","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions","status":"NOT_YET_RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2026-04-19","conditions":["Essential Hypertension"],"enrollment":48,"completionDate":"2026-06-17"},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT05413057","phase":"","title":"An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-06-23","conditions":["Hypertension,Essential"],"enrollment":20000,"completionDate":"2026-06"},{"nctId":"NCT04554953","phase":"","title":"A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2020-04-13","conditions":["Hypertension and Dyslipidemia"],"enrollment":10877,"completionDate":"2022-05-31"},{"nctId":"NCT03254914","phase":"","title":"Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-08-09","conditions":["Hypertension"],"enrollment":3554,"completionDate":"2019-02-28"},{"nctId":"NCT05878561","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-11-09","conditions":["Essential Hypertension"],"enrollment":248,"completionDate":"2024-12-02"},{"nctId":"NCT05930028","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2023-07-13","conditions":["Essential Hypertension","Primary Hypercholesterolemia"],"enrollment":148,"completionDate":"2024-09-05"},{"nctId":"NCT05173025","phase":"PHASE4","title":"Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-01-01","conditions":["Hypertension","Atherosclerosis","Diabetes Mellitus, Type 2","Renin Hypertension"],"enrollment":42,"completionDate":"2023-12-31"},{"nctId":"NCT05086549","phase":"","title":"An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-09-29","conditions":["Diabetic Kidney Disease","Proteinuria","Hypertension,Essential"],"enrollment":360,"completionDate":"2023-06-05"},{"nctId":"NCT02022774","phase":"","title":"Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-04","conditions":["Hypertension"],"enrollment":90,"completionDate":"2017-06-30"},{"nctId":"NCT02913794","phase":"","title":"Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-10-11","conditions":["Cardiovascular Diseases","Hyperlipidemias"],"enrollment":541,"completionDate":"2018-03-29"},{"nctId":"NCT05372380","phase":"PHASE1","title":"A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-05-09","conditions":["Hypertension","Hypercholesterinemia"],"enrollment":32,"completionDate":"2022-06-30"},{"nctId":"NCT02620306","phase":"PHASE3","title":"A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-02-11","conditions":["Chronic Kidney Disease"],"enrollment":351,"completionDate":"2022-05-11"},{"nctId":"NCT05097794","phase":"PHASE1","title":"A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between \"BR1015-1\" and \"BR1015-2\" in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-08-16","conditions":["Hypertension"],"enrollment":31,"completionDate":"2021-10-22"},{"nctId":"NCT03991442","phase":"PHASE3","title":"BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2019-06-17","conditions":["Essential Hypertension"],"enrollment":257,"completionDate":"2021-03-02"},{"nctId":"NCT03649646","phase":"","title":"FimasaRtan-basEd BP Targets After Drug SwitcHing","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-07-03","conditions":["Essential Hypertension"],"enrollment":4542,"completionDate":"2020-10-29"},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":["The Elderly (≥ 70 Years) With Essential Hypertension"],"enrollment":241,"completionDate":"2019-12-09"},{"nctId":"NCT03609294","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-07-18","conditions":["Hypertension","Diabetes"],"enrollment":67,"completionDate":"2019-06-30"},{"nctId":"NCT03338426","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-01-15","conditions":["Essential Hypertension, Dyslipidemia"],"enrollment":133,"completionDate":"2019-04-22"},{"nctId":"NCT03231293","phase":"","title":"Fimasartan Blood Pressure Lowering After Acute Stroke","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-28","conditions":["Hypertension","Ischemic Stroke","Transient Ischemic Attack"],"enrollment":1035,"completionDate":"2019-04-05"},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":["Hypertension","Dyslipidemias"],"enrollment":150,"completionDate":"2018-12-20"},{"nctId":"NCT03156842","phase":"PHASE3","title":"Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-05-29","conditions":["Essential Hypertension","Dyslipidemia"],"enrollment":138,"completionDate":"2018-12-07"},{"nctId":"NCT02248961","phase":"PHASE3","title":"Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05","conditions":["Arterial Hypertension"],"enrollment":179,"completionDate":"2015-08"},{"nctId":"NCT02385721","phase":"","title":"Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2013-05","conditions":["Essential Hypertension"],"enrollment":601,"completionDate":"2018-04"},{"nctId":"NCT03629067","phase":"PHASE1","title":"Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2018-09-13","conditions":["Pharmacokinetics"],"enrollment":60,"completionDate":"2018-12-27"},{"nctId":"NCT02704702","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-03","conditions":["Hypertension"],"enrollment":36,"completionDate":"2016-06"},{"nctId":"NCT03390465","phase":"PHASE1","title":"Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-12-15","conditions":["Drug-Drug Interaction"],"enrollment":36,"completionDate":"2018-01-30"},{"nctId":"NCT01384747","phase":"PHASE4","title":"Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)","status":"TERMINATED","sponsor":"Seung-Jung Park","startDate":"2011-07","conditions":["Coronary Artery Disease"],"enrollment":186,"completionDate":"2018-03"},{"nctId":"NCT00922480","phase":"PHASE3","title":"Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2008-12","conditions":["Hypertension"],"enrollment":506,"completionDate":"2009-09"},{"nctId":"NCT00922441","phase":"PHASE2","title":"A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2008-12","conditions":["Essential Hypertension"],"enrollment":92,"completionDate":"2009-08"},{"nctId":"NCT03250052","phase":"PHASE1","title":"A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2017-08-14","conditions":["Hypertension"],"enrollment":39,"completionDate":"2017-11-21"},{"nctId":"NCT02994745","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-12-23","conditions":["Hypertension, Hyperlipidemia"],"enrollment":60,"completionDate":"2017-08"},{"nctId":"NCT02920047","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-10","conditions":["Hypertension"],"enrollment":60,"completionDate":"2017-01"},{"nctId":"NCT02378064","phase":"PHASE4","title":"Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation","status":"COMPLETED","sponsor":"CHEOL WHAN LEE, M.D., Ph.D","startDate":"2015-05","conditions":["Inflammation Plaque, Atherosclerotic","Coronary Disease","Renin-Angiotensin System"],"enrollment":50,"completionDate":"2017-12"},{"nctId":"NCT03294070","phase":"PHASE4","title":"Fimasartan Plus Amlodipine on Hemodynamic Parameters and Arterial Stiffness in Patients With Hypertension","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2017-09","conditions":["Arterial Hypertension"],"enrollment":53,"completionDate":"2018-08"},{"nctId":"NCT02995720","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-08-26","conditions":["Hypertension, Hyperlipidemia"],"enrollment":60,"completionDate":"2017-05-30"},{"nctId":"NCT03219632","phase":"","title":"Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2012-06-05","conditions":["Left Ventricular Hypertrophy","Hypertension"],"enrollment":72,"completionDate":"2017-05-30"},{"nctId":"NCT02495324","phase":"PHASE4","title":"Fimasartan Achieving SBP Target (FAST) Study","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-06","conditions":["Essential,Hypertension"],"enrollment":369,"completionDate":"2017-05"},{"nctId":"NCT02312375","phase":"NA","title":"Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-03","conditions":["Diabetes Mellitus","Hypertension"],"enrollment":46,"completionDate":"2017-03"},{"nctId":"NCT02166814","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-08","conditions":["Essential Hypertension, Dyslipidemia"],"enrollment":140,"completionDate":"2015-09"},{"nctId":"NCT02958631","phase":"PHASE4","title":"Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan","status":"UNKNOWN","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2014-11","conditions":["Hypertension"],"enrollment":40,"completionDate":"2017-04"},{"nctId":"NCT01736488","phase":"PHASE4","title":"Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-10","conditions":["Hypertension"],"enrollment":25,"completionDate":""},{"nctId":"NCT01671020","phase":"PHASE1","title":"Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-06","conditions":["Healthy"],"enrollment":16,"completionDate":"2012-07"},{"nctId":"NCT02147704","phase":"PHASE4","title":"Effect of High- and Low-sodium Intake on the Pharmacokinetics and Pharmacodynamic Effects of Fimasartan","status":"COMPLETED","sponsor":"DongGuk University","startDate":"2014-05","conditions":["Hypertension"],"enrollment":27,"completionDate":"2014-09"},{"nctId":"NCT02222480","phase":"PHASE2","title":"A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-10","conditions":["Hypertension"],"enrollment":103,"completionDate":"2015-06"},{"nctId":"NCT01518998","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2011-08","conditions":["Hypertension"],"enrollment":420,"completionDate":"2013-11"},{"nctId":"NCT01672476","phase":"PHASE3","title":"A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-04","conditions":["Hypertension"],"enrollment":293,"completionDate":"2013-04"},{"nctId":"NCT02566187","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-08","conditions":["Hypertension","Hyperlipidemia"],"enrollment":99,"completionDate":"2015-10"},{"nctId":"NCT02569814","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-09","conditions":["Hypertension","Hyperlipidemia"],"enrollment":100,"completionDate":"2015-12"},{"nctId":"NCT01691118","phase":"PHASE4","title":"A Trial of Fimasartan for Early Diastolic Heart Failure","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2012-09","conditions":["Hypertension"],"enrollment":60,"completionDate":"2015-08"},{"nctId":"NCT02152306","phase":"PHASE3","title":"Fimasartan/Amlodipine Combination Phase III","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-04","conditions":["Essential Hypertension"],"enrollment":143,"completionDate":"2015-07"},{"nctId":"NCT02397538","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-02","conditions":["Hypertension"],"enrollment":50,"completionDate":"2015-04"},{"nctId":"NCT02397590","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-03","conditions":["Hypertension"],"enrollment":36,"completionDate":"2015-06"},{"nctId":"NCT02466490","phase":"PHASE3","title":"Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Stendhal Americas, S.A.","startDate":"2013-04","conditions":["Hypertension, Essential"],"enrollment":272,"completionDate":"2014-02"},{"nctId":"NCT02403349","phase":"PHASE4","title":"Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol","status":"UNKNOWN","sponsor":"Ajou University School of Medicine","startDate":"2012-05","conditions":["Blood Pressure","Ischemic Stroke"],"enrollment":105,"completionDate":"2015-09"},{"nctId":"NCT02205151","phase":"PHASE1","title":"To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-07","conditions":["Hypertension"],"enrollment":86,"completionDate":"2014-09"},{"nctId":"NCT02205190","phase":"PHASE1","title":"to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2014-07","conditions":["Hypertension"],"enrollment":81,"completionDate":"2014-09"},{"nctId":"NCT01878201","phase":"PHASE2","title":"A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2013-05","conditions":["Essential Hypertension"],"enrollment":75,"completionDate":"2014-02"},{"nctId":"NCT01921946","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2013-08","conditions":["Hypertension"],"enrollment":50,"completionDate":"2013-10"},{"nctId":"NCT01135212","phase":"PHASE3","title":"The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2010-04","conditions":["Hypertension"],"enrollment":290,"completionDate":"2011-05"},{"nctId":"NCT01589380","phase":"PHASE4","title":"A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2012-04","conditions":["Critical Stenosis of Aortic Valve"],"enrollment":100,"completionDate":"2014-12"},{"nctId":"NCT01148368","phase":"PHASE1","title":"A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2010-06","conditions":["Renal Impairment"],"enrollment":16,"completionDate":"2011-07"},{"nctId":"NCT01146938","phase":"PHASE1","title":"A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2010-05","conditions":["Essential Hypertension","Hepatic Impairment"],"enrollment":18,"completionDate":"2011-02"},{"nctId":"NCT01258673","phase":"PHASE3","title":"A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2010-11","conditions":["Essential Hypertension"],"enrollment":263,"completionDate":""},{"nctId":"NCT01289886","phase":"PHASE1","title":"Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2003-09","conditions":["Essential Hypertension"],"enrollment":40,"completionDate":"2003-12"},{"nctId":"NCT01289899","phase":"PHASE1","title":"Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2004-01","conditions":["Essential Hypertension"],"enrollment":16,"completionDate":"2004-02"},{"nctId":"NCT01007409","phase":"PHASE1","title":"A Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-10","conditions":["Healthy"],"enrollment":24,"completionDate":""},{"nctId":"NCT00937534","phase":"PHASE1","title":"Study to Compare and Assess the Safety and Pharmacokinetic Characteristics After Oral Administration of Fimasartan (BR-A-657∙K) in Healthy Elderly and Young Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-01","conditions":["Essential Hypertension"],"enrollment":22,"completionDate":"2009-08"},{"nctId":"NCT00991783","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-08","conditions":["Essential Hypertension"],"enrollment":14,"completionDate":"2009-11"},{"nctId":"NCT00991705","phase":"PHASE1","title":"A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-07","conditions":["Essential Hypertension"],"enrollment":28,"completionDate":"2009-09"},{"nctId":"NCT00938262","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-04","conditions":["Essential Hypertension"],"enrollment":24,"completionDate":"2009-08"},{"nctId":"NCT00923533","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Fimasartan and Hydrochlorothiazide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-03","conditions":["Essential Hypertension"],"enrollment":34,"completionDate":"2009-08"},{"nctId":"NCT00938197","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-06","conditions":["Essential Hypertension"],"enrollment":34,"completionDate":"2009-08"},{"nctId":"NCT00938132","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2009-07","conditions":["Essential Hypertension"],"enrollment":15,"completionDate":"2009-09"},{"nctId":"NCT00937651","phase":"PHASE2","title":"Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2005-04","conditions":["Essential Hypertension"],"enrollment":81,"completionDate":"2006-06"},{"nctId":"NCT00923611","phase":"PHASE2","title":"Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2007-09","conditions":["Hypertension"],"enrollment":182,"completionDate":"2008-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P58222188P","CHEBI":"CHEBI:136044","INN_ID":"8678","UMLSCUI":"C2825622","ChEMBL_ID":"CHEMBL1951143","KEGG_DRUG":"D10556","DRUGBANK_ID":"DB09279","PUBCHEM_CID":"9870652","SECONDARY_CAS_RN":"1020110-23-9","MESH_SUPPLEMENTAL_RECORD_UI":"C558933"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.5 hours","clearance":"9.6 mL/min/kg","volumeOfDistribution":"0.6 L/kg"},"publicationCount":133,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C09CA10","allCodes":["C09CA10","C09DA10","C09DB09","C10BX16"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov","pmid":"40947318","title":"Efficacy and Safety of Fimasartan, Atorvastatin, and Ezetimibe Combination Therapy in Patients With Hypertension and Dyslipidemia: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.","journal":"Clinical therapeutics"},{"date":"2025 Sep 8","pmid":"40923512","title":"Letter to the Editor: Fimasartan-Induced Liver Injury and Update on Hepatotoxicity Risks.","journal":"Journal of Korean medical science"},{"date":"2025 Dec","pmid":"40818015","title":"Eco-friendly Nano-scale Bio-analytical Insights for Spectrofluorimetric Estimation of Fimasartan Using Integrated Approach of Enhanced Microwave-assisted Hantzsch Reaction and Multicolored Analytical Chemistry.","journal":"Journal of fluorescence"},{"date":"2024 Dec 11","pmid":"39771560","title":"Heterotropic Activation of Cytochrome P450 3A4 by Perillyl Alcohol.","journal":"Pharmaceutics"},{"date":"2024 Nov","pmid":"39405004","title":"Novel Fimasartan Fluidized Solid Dispersion and Its Tablet: Preparation, Crystallinity, Solubility, Dissolution, and Pharmacokinetics in Beagle Dogs.","journal":"European journal of drug metabolism and pharmacokinetics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kanarb (Fimasartan) is a small molecule drug that targets the Type-1 angiotensin II receptor. It is used to treat hypertensive disorder, a condition characterized by high blood pressure. The commercial status of Kanarb is unknown, but it is likely patented as it is not widely recognized. Key safety considerations include its half-life of 5.5 hours, although its bioavailability and off-patent status are unknown. As a relatively new drug, its long-term effects and interactions are still being studied.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"Korean Food and Drug Administration (KFDA)","status":"approved","approval_date":"2010-09-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}